| 95.48 0.06 (0.06%) | 11-11 15:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 111.59  |
1-year : | 130.33 |
| Resists | First : | 95.54 |
Second : | 111.59 |
| Pivot price | 94.94 |
|||
| Supports | First : | 94.76 |
Second : | 94.29 |
| MAs | MA(5) : | 95.28 |
MA(20) : | 94.89 |
| MA(100) : | 73.3 |
MA(250) : | 56.21 |
|
| MACD | MACD : | 2.3  |
Signal : | 3.1 |
| %K %D | K(14,3) : | 91.4 |
D(3) : | 87.6 |
| RSI | RSI(14): 79.7 |
|||
| 52-week | High : | 95.54 | Low : | 33.18 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MRUS ] has closed below upper band by 8.7%. Bollinger Bands are 88.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 95.56 - 95.91 | 95.91 - 96.2 |
| Low: | 93.94 - 94.39 | 94.39 - 94.76 |
| Close: | 94.74 - 95.44 | 95.44 - 96 |
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Sat, 08 Nov 2025
Assessing Merus (MRUS) Valuation After Its Recent Surge in Share Price - simplywall.st
Tue, 04 Nov 2025
Truist Financial Reaffirms Their Hold Rating on Merus (MRUS) - The Globe and Mail
Fri, 24 Oct 2025
Merus (NASDAQ: MRUS) announces 100% responses in 1L left-sided mCRC with petosemtamab - Stock Titan
Fri, 24 Oct 2025
Merus N.V. Reports Promising Interim Clinical Data for Petosemtamab in Metastatic Colorectal Cancer - Quiver Quantitative
Tue, 21 Oct 2025
Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V. - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 76 (M) |
| Held by Insiders | 6.563e+007 (%) |
| Held by Institutions | 2.2 (%) |
| Shares Short | 4,330 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.4453e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 250 % |
| Return on Equity (ttm) | -23.2 % |
| Qtrly Rev. Growth | 5.623e+007 % |
| Gross Profit (p.s.) | 16.19 |
| Sales Per Share | -38.53 |
| EBITDA (p.s.) | -4.19206e+007 |
| Qtrly Earnings Growth | -5.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -313 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -2.48 |
| Price to Cash Flow | 10.79 |
| Dividend | 0 |
| Forward Dividend | 2.21e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|